» Articles » PMID: 25430879

Type I IFN Gene Delivery Suppresses Regulatory T Cells Within Tumors

Overview
Date 2014 Nov 29
PMID 25430879
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Type I interferon (IFN) is a pleiotropic cytokine regulating the cancer cell death and immune response. IFN-α can, as we have also reported, effectively induce an antitumor immunity by the activation of tumor-specific T cells and maturation of dendritic cells in various animal models. Unknown, however, is how the type I IFN alters the immunotolerant microenvironment in the tumors. Here, we found that intratumoral IFN-α gene transfer significantly decreased the frequency of regulatory T cells (Tregs) per CD4(+) T cells in tumors. The concentration of a Treg-inhibitory cytokine, interleukin (IL)-6, was correlated with the IFN-α expression level in tumors, and intratumoral CD11c(+) cells produced IL-6 in response to IFN-α stimulation. To confirm the role of IL-6 in the suppression of Tregs in tumors, an anti-IL-6 receptor antibody was administered in IFN-α-treated mice. The antibody increased the frequency of Tregs in the tumors, and attenuated systemic tumor-specific immunity induced by IFN-α. Furthermore, the IFN-α-mediated IL-6 production increased the frequency of Th17 cells in the tumors, which may be one of the mechanisms for the reduction of Tregs. The study demonstrated that IFN-α gene delivery creates an environment strongly supporting the enhancement of antitumor immunity through the suppression of Tregs.

Citing Articles

Impacts of combining PD-L1 inhibitor and radiotherapy on the tumour immune microenvironment in a mouse model of esophageal squamous cell carcinoma.

Yin Z, Zhang H, Zhang K, Yue J, Tang R, Wang Y BMC Cancer. 2025; 25(1):474.

PMID: 40087599 DOI: 10.1186/s12885-025-13801-0.


Toll-Like receptor 3-mediated interferon-β production is suppressed by oncostatin m and a broader epithelial-mesenchymal transition program.

Chernosky N, Tamagno I, Polak K, Ricky Chan E, Yuan X, Jackson M Breast Cancer Res. 2024; 26(1):167.

PMID: 39593161 PMC: 11590466. DOI: 10.1186/s13058-024-01918-2.


Targeting cytokine and chemokine signaling pathways for cancer therapy.

Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K Signal Transduct Target Ther. 2024; 9(1):176.

PMID: 39034318 PMC: 11275440. DOI: 10.1038/s41392-024-01868-3.


Induction of antiviral interferon-stimulated genes by neuronal STING promotes the resolution of pain in mice.

Defaye M, Bradaia A, Abdullah N, Agosti F, Iftinca M, Delanne-Cumenal M J Clin Invest. 2024; 134(9).

PMID: 38690737 PMC: 11060736. DOI: 10.1172/JCI176474.


Recent Advances of RNA mA Modifications in Cancer Immunoediting and Immunotherapy.

Ma S, Barr T, Yu J Cancer Treat Res. 2023; 190:49-94.

PMID: 38112999 DOI: 10.1007/978-3-031-45654-1_3.


References
1.
Rossi J, Negrier S, James N, Kocak I, Hawkins R, Davis H . A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer. 2010; 103(8):1154-62. PMC: 2967052. DOI: 10.1038/sj.bjc.6605872. View

2.
Mullen C, Coale M, Levy A, Stetler-Stevenson W, Liotta L, Brandt S . Fibrosarcoma cells transduced with the IL-6 gene exhibited reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res. 1992; 52(21):6020-4. View

3.
Hatanaka K, Suzuki K, Miura Y, Yoshida K, Ohnami S, Kitade Y . Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer. J Gene Med. 2004; 6(10):1139-48. DOI: 10.1002/jgm.602. View

4.
Grivennikov S, Karin E, Terzic J, Mucida D, Yu G, Vallabhapurapu S . IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009; 15(2):103-13. PMC: 2667107. DOI: 10.1016/j.ccr.2009.01.001. View

5.
Chari A, Pri-Chen H, Jagannath S . Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma. Clin Lymphoma Myeloma Leuk. 2013; 13(3):333-7. DOI: 10.1016/j.clml.2012.12.010. View